Summary & Overview
HCPCS S0177: Levamisole Hydrochloride, Oral, 50 mg
HCPCS Level II code S0177 designates levamisole hydrochloride, oral, 50 mg. This HCPCS Level II drug code identifies a specific oral medication formulation used in clinical settings for antiparasitic treatment and historically as an immunomodulatory adjunct in oncology. Nationally, a clearly defined HCPCS drug code matters for accurate billing, inventory tracking, and payer adjudication when medications are dispensed in outpatient clinics or purchased through pharmacies.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context and the sites of service where billing typically occurs. The publication summarizes standard billing considerations tied to HCPCS drug coding, highlights where this code fits within drug service lines, and identifies the types of benchmarks and policy updates that commonly affect HCPCS Level II drug reimbursement and coverage decisions.
This national summary is intended to orient billing managers, clinicians in outpatient and oncology settings, and revenue cycle staff to the purpose of S0177, the service settings in which it appears, and the payer landscape relevant to coverage and billing practices. Data not available in the input are noted where specific payer policies, associated taxonomies, ICD-10 mappings, and utilization benchmarks would normally appear.
Billing Code Overview
HCPCS Level II code S0177 represents levamisole hydrochloride, oral, 50 mg, a pharmaceutical product billed as a specific drug supply. The service type is medication dispensing/oral chemotherapy or antiparasitic agent administration by prescription or clinic dispensing. The typical site of service is outpatient clinic, infusion/oncology clinic when used as adjunctive therapy, or pharmacy dispensing for oral administration.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a history of colorectal carcinoma presents for adjunctive oral therapy. The oncology team prescribes levamisole hydrochloride 50 mg tablets to be taken orally on a specified schedule in combination with other chemotherapeutic agents. The medication is dispensed by the clinic or pharmacy and administered in the outpatient oncology setting. Typical workflow: physician documents indication and dosing in the outpatient chart, the medication is ordered in the electronic medical record, pharmacy verifies dosing and drug interactions, medication is dispensed to the patient or provided during the clinic visit, and nursing documents patient education and administration adherence. Follow-up visits assess tolerance, adverse effects (such as gastrointestinal upset, leukopenia, or dermatologic reactions), and laboratory monitoring including complete blood count and liver function tests as clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Used when no specific modifier applies to the verbal claim conditions for this HCPCS code. |
22 | Increased procedural services | For unusually extensive services related to additional clinician time or complexity associated with medication management or counseling. |